Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Hereditary Hematological Disorders Report Coverage
2.2 Thalassemia – Overview
2.3 Hemophilia B – Overview
2.4 Sickle Cell Disease – Overview
3 Therapeutics Development
3.1 Thalassemia
3.2 Hemophilia B – Therapeutics Development
3.3 Sickle Cell Disease – Therapeutics Development
4 Therapeutics Assessment
4.1 Thalassemia – Therapeutics Assessment
4.2 Hemophilia B – Therapeutics Assessment
4.3 Sickle Cell Disease – Therapeutics Assessment
5 Companies Involved in Therapeutics Development
5.1 Thalassemia – Companies Involved in Therapeutics Development
5.2 Hemophilia B – Companies Involved in Therapeutics Development
5.3 Sickle Cell Disease – Companies Involved in Therapeutics Development
6 Dormant Projects
6.1 Thalassemia – Dormant Projects
6.2 Hemophilia B – Dormant Projects
6.3 Sickle Cell Disease – Dormant Projects
7 Discontinued Products
7.1 Thalassemia – Discontinued Products
7.2 Hemophilia B – Discontinued Products
8 Product Development Milestones
8.1 Thalassemia – Product Development Milestones
8.2 Hemophilia B – Product Development Milestones
8.3 Sickle Cell Disease – Product Development Milestones
9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer